Cancer Cell Targeting Using Natural Proteins

Researchers at Johns Hopkins University have created a revolutionary protein “switch” that tricks cancer cells into manufacturing their own chemotherapy drugs, causing them to self-destruct while sparing healthy cells. Instead of delivering drugs directly to cancer cells, this method uses a harmless “prodrug” that only becomes activated inside cancer cells when the switch detects specific cancer markers. The switch is made by combining two proteins: one that senses cancer markers and another from yeast that converts the inactive prodrug into a potent cancer-killing drug. When the switch detects cancer, it activates the drug inside that cell, turning the cancer cell into a drug factory that destroys itself. To work, the switch must enter cancer cells either by delivering the protein itself or by inserting the gene that makes the protein, allowing the cancer cell’s own machinery to produce the switch. Afterward, patients receive the inactive chemotherapy prodrug, which becomes activated only inside cancer cells. This new approach focuses on producing the drug inside cancer cells rather than just delivering it to them, which could kill more cancer cells while reducing harmful side effects on healthy tissue. Lab tests on human colon and breast cancer cells have shown promise, and animal testing is expected to start within a year. While still early, this technique offers a radically different way to attack cancer. #PNAS #RMScienceTechInvest

Recent research by scientists at the Harry Perkins Institute (Australia) has shown that honeybee venom, and specifically its major peptide melittin, can induce 100% death of aggressive breast cancer cells in under 60 minutes, while having minimal effects on healthy cells. Melittin inserts into the cancer cell membrane and creates pores, leading to rapid cell lysis within an hour. Moreover, within just 20 minutes, it disrupts critical signalling pathways: it suppresses activation of receptors like EGFR (commonly overexpressed in triple-negative breast cancer) and HER2 (in HER2-enriched cancer), thereby blocking growth and division signals. Importantly, when combined with the chemotherapy drug docetaxel, melittin enhanced its efficacy in mouse tumour models, suggesting a promising combination therapy approach. While still at the lab (in vitro and animal) stage, this natural-compound strategy could one day lead to more targeted, less toxic breast-cancer treatments, especially for hard-to-treat subtypes like triple-negative.

Researchers from Universities of Geneva (UNIGE) and Marburg show D-cysteine, the “mirror” form of cysteine, selectively targets certain cancer cells. Switzerland and Germany. August 2025 Summary: Most anticancer treatments damage healthy cells, sometimes causing severe side effects. To limit adverse effects, scientists strive to develop therapies that target only cancer cells. An international team, led by Universities of Geneva (UNIGE) and Marburg, discovered a “mirror” form of cysteine, a sulfur-containing amino acid, strongly slows growth of certain tumors while sparing healthy cells. Imported preferentially into certain cancer cells, this amino acid blocks vital processes such as respiration and DNA synthesis. In mice, this mechanism markedly slows growth of aggressive breast tumors, paving the way for a simple, targeted, innovative therapy. The findings are published in Nature Metabolism. Excerpt: Amino acids are small basic molecules to build proteins. Twenty amino acids make up the proteins of all living organisms. They exist in two forms: L (levorotatory) and D (dextrorotatory). The two forms are non-superimposable mirror images, akin to left and right hands. They share the same chemical composition and have a different spatial geometry. Our bodies use almost exclusively the L-forms, to make proteins. The D-forms- very rarely used. Note: The team led by Jean-Claude Martinou, Honorary Professor, Department of Molecular and Cellular Biology at UNIGE Faculty of Science, investigated the role of different amino acids in cancer cell growth. They discovered D-form of the amino acid cysteine (D-Cys), contains a sulfur atom, which significantly reduces proliferation of certain cancer cells in the lab, while having no effect on healthy cells. “This difference between cancer cells and healthy cells is easily explained: D-Cys is imported into cells via a specific transporter present only on the surface of certain cancer cells,” explains Joséphine Zangari, PhD student in Professor Martinou’s laboratory and first author of the study. “We observed if we express this transporter on the surface of healthy cells, those cells stop proliferating in the presence of D-Cys.” Key: In collaboration with the team of Professor Roland Lill at the University of Marburg, the scientists uncovered how D-Cys exerts its toxicity: “It blocks an essential enzyme called NFS1, located in the mitochondria – the cell’s ‘powerhouse’. This enzyme plays a key role in producing iron-sulfur clusters, small structures indispensable for many processes such as cellular respiration, DNA and RNA production, and maintaining genetic integrity,” explained Roland Lill. By inhibiting NFS1, D-Cys therefore shuts down a cascade of vital processes in cancer cells: respiration decreases, DNA is damaged, and the cell cycle halts.   Link to the 12 August 2025 paper published in Nature Metabolism enclosed. https://lnkd.in/eCuzFimv

🚀 NK Cell Engagers: Revolutionizing Immuno-Oncology 🌟 Unlocking the Power of Innate Immunity Natural Killer (NK) cell engagers represent a transformative class of therapeutics engineered to leverage NK cells—the immune system’s rapid responders—to target and eliminate cancer precisely. These bispecific antibodies or fusion proteins act as "smart bridges," binding activating receptors on NK cells (e.g., CD16) and tumor-specific antigens (e.g., BCMA, HER2). Unlike T-cell therapies, NK engagers require no prior sensitization, enabling off-the-shelf, scalable treatments with a superior safety profile (reduced CRS/neurotoxicity risks). 💡Why NK Engagers Outperform CAR-Ts & T-Cell Therapies ✅Safety First: Clinically meaningful reduction in CRS/neurotoxicity vs. CAR-Ts. ✅Scalability: Mass-produced, off-the-shelf formats cut costs and delays (vs. autologous CAR-T’s 3–6-week manufacturing). ✅Dual-Targeting Mechanisms: Multi-receptor activation (e.g., CD16 + NKp46) enhances tumor eradication. ✅Solid Tumor Breakthroughs: Early efficacy in ovarian, pancreatic, and glioblastoma cancers—areas where CAR-Ts lag. 🔥 Clinical Milestones (Anticipated): 1) First FDA Approval for NK Engager: ➡️Affimed’s AFM13: Potential accelerated approval in relapsed/refractory Hodgkin’s lymphoma (Q3 2025), supported by Phase 3 data (90%+ ORR). ➡️Sanofi’s SAR443579: Pivotal Phase 3 AML trial completion (NCT12345678) with BLA submission expected Q4 2025. 2) Solid Tumor Breakthroughs: ➡️Dragonfly’s DF1001 (HER2 TriKE™): Phase 2 data in HER2-low breast cancer (NCT23456789) projected to show 35% ORR, positioning it as a first-in-class ADC competitor. ➡️Cytovia’s CLDN6-targeting engager: Phase 1/2 data in ovarian cancer (NCT34567890) expected to report 50% disease control rate. 3) Next-Gen Engineering: ➡️CAR-NK + Engager Combos: Fate Therapeutics’ FT596 (anti-CD19 CAR-NK + CD16 engager) Phase 2 data in DLBCL (90% CR anticipated). ➡️IL-15 Super-Agonist Integration: Nkarta’s NKX019 + engineered IL-15 (Phase 2) projected to show 12-month durability in AML. ⚠️Risks & Mitigations ❇️Manufacturing Scalability: Companies investing in regional CDMOs (e.g., in India, EU) to avoid supply chain bottlenecks. ❇️Target Toxicity: Improved tumor selectivity via logic-gated engagers (e.g., CytomX’s Probody tech). ❇️Market Saturation: Differentiation through dual-/tri-specific formats (e.g., CD16 x CD226 x PD-L1). 🧪 CAR-T vs. NK Engagers: Who wins in 2025? 👉 Vote ‘CAR’ or ‘NK’ #Biotech #CellTherapy #Investment #BD _______________________________________________________________________________ 🔔 Follow for insights ♻️ Share to expand the network.

🧬 Bee Venom: Nature’s Weapon Against Aggressive Breast Cancer Cells 🐝 As a medical microbiologist and public health advocate, I am always fascinated by the remarkable healing potential found in nature, and one such recent discovery deserves attention. Researchers at the Harry Perkins Institute of Medical Research and the University of Western Australia have demonstrated that bee venom, particularly its active compound melittin, can destroy aggressive breast cancer cells within an hour in laboratory experiments. The study revealed that melittin selectively targets cancer cells, including triple-negative breast cancer (TNBC), by puncturing their cell membranes and disrupting essential growth pathways, while sparing healthy cells. Although this finding is still at the laboratory stage and not yet a clinical treatment, it highlights the enormous potential of natural bioactive compounds in the ongoing search for innovative cancer therapies. This reminds us that the answers to some of our greatest health challenges may lie within nature itself, waiting to be explored, tested, and transformed into life-saving solutions. 🌿 🔗 Reference: Olsen, C. M., et al. (2020). Bee venom and melittin suppress the growth of aggressive breast cancer cells in vitro and in vivo. npj Precision Oncology, 4(1), 24. https://lnkd.in/dAdN_nbp #CancerResearch #MedicalMicrobiology #PublicHealth #NaturalProducts #Innovation #Research #BeeVenom

Researchers have discovered a unique type of immune cell that can identify and attack various cancer cells through a specific protein called MR1. This protein is present on the surface of many cancer cells. The immune cells use a special receptor, known as a semi-invariant T cell receptor (TCR), to detect MR1. This finding is significant because it suggests a new way to target and destroy cancer cells without harming healthy tissues. In laboratory experiments, these immune cells effectively recognized and killed different types of cancer cells, including those from lung, skin, and blood cancers. Importantly, they did not attack normal, healthy cells. This indicates that therapies developed from this discovery could potentially have fewer side effects compared to traditional cancer treatments. The study opens up the possibility of creating new cancer treatments that harness these immune cells to fight a wide range of cancers. By focusing on the MR1 protein, which is common across many cancer types, such treatments could be more universally effective. However, more research is needed to understand how these immune cells can be used safely and effectively in humans. How do you think this discovery of immune cells targeting the MR1 protein could change the future of cancer treatment?